RESEARCH-USE BIOSIMILAR ANTIBODY

Vunakizumab

Monoclonal antibody · IgG1

IL17AIgG1RUO

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.

TARGETIL17A
YMonoclonal antibody
CATALOGSC-BS-032
CATALOG NUMBERSC-BS-032
MOLECULAR WEIGHTApprox. 146.38 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.

Vunakizumab is a recombinant research-use antibody directed against IL17A.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Vunakizumab | StellaCyte